Somatostatin and its long-acting analogue octreotide have been used in various diarrheal disorders, including neoplastic and nonneoplastic diseases of the gastrointestinal tract. In two insulin-dependent diabetic patients with autonomic neuropathy and chronic steatorrheic diarrhea refractory to conventional medications, subcutaneous administration of octreotide markedly improved the volume and frequency of stools in both patients. This change was accompanied by a clear improvement in their rapid gastrointestinal tract transit times. The treatment also greatly improved their orthostatic hypotension. No adverse effects of octreotide were observed after treatment for 7 months in one patient and 2 months in the other.
(Arch Intern Med. 1994;154:1863-1867)
Nakabayashi H, Fujii S, Miwa U, Seta T, Takeda R. Marked Improvement of Diabetic Diarrhea With the Somatostatin Analogue Octreotide. Arch Intern Med. 1994;154(16):1863–1867. doi:10.1001/archinte.1994.00420160103014
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.